Biotech · Public company · South San Francisco, CA, US

Allogene Therapeutics, Inc.

Ticker ALLO · SEC CIK 0001737287

Track this companyFree. Adds Allogene Therapeutics, Inc. to your Dealase workspace and tells you when its record changes.

Clinical trials95 recruiting or active

Pipeline programs26From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline26

ALLO-501APhase 2 · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-501APhase 2 · Relapsed/Refractory Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-605Phase 2 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-647Phase 2 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-647Phase 2 · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-647Phase 2 · Relapsed/Refractory Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
cemacabtagene ansegedleucelPhase 2 · Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 2 · Relapsed/Refractory Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 2 · Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 2 · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 2 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Relapsed/Refractory Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 2 · Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic LymphomaClinicalTrials.gov · fetched Nov 12, 2026
Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™Phase 2 · Large B-cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-316Phase 1 · Advanced/Metastatic Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-329Phase 1 · Systemic Lupus Erythematosus (With and Without Nephritis)ClinicalTrials.gov · fetched Nov 12, 2026
ALLO-501Phase 1 · Relapsed/Refractory Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-647Phase 1 · Advanced/Metastatic Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
ALLO-715Phase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Systemic Lupus Erythematosus (With and Without Nephritis)ClinicalTrials.gov · fetched Nov 12, 2026
CyclophosphamidePhase 1 · Advanced/Metastatic Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Systemic Lupus Erythematosus (With and Without Nephritis)ClinicalTrials.gov · fetched Nov 12, 2026
FludarabinePhase 1 · Advanced/Metastatic Clear Cell Renal Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
NirogacestatPhase 1 · Relapsed/Refractory Multiple MyelomaClinicalTrials.gov · fetched Nov 12, 2026

Clinical trials9

A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune DiseasePHASE1 · RECRUITING · started Nov 13, 2025ClinicalTrials.gov NCT07085104 · fetched Nov 12, 2026
Follow-Up for Study Participants Treated With an Allogeneic CAR T Cell ProductENROLLING_BY_INVITATION · started Jan 31, 2025ClinicalTrials.gov NCT06925685 · fetched Nov 12, 2026
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCLPHASE2 · RECRUITING · started Jun 18, 2024ClinicalTrials.gov NCT06500273 · fetched Nov 12, 2026
Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell TherapyPHASE2 · TERMINATED · started Nov 1, 2023ClinicalTrials.gov NCT05714345 · fetched Nov 12, 2026
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple MyelomaPHASE1_PHASE2 · TERMINATED · started Jun 6, 2021ClinicalTrials.gov NCT05000450 · fetched Nov 12, 2026
Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaPHASE1 · ACTIVE_NOT_RECRUITING · started Feb 24, 2021ClinicalTrials.gov NCT04696731 · fetched Nov 12, 2026
Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)PHASE1_PHASE2 · ACTIVE_NOT_RECRUITING · started May 21, 2020ClinicalTrials.gov NCT04416984 · fetched Nov 12, 2026
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)PHASE1 · COMPLETED · started Sep 23, 2019ClinicalTrials.gov NCT04093596 · fetched Nov 12, 2026
Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular LymphomaPHASE1 · COMPLETED · started May 1, 2019ClinicalTrials.gov NCT03939026 · fetched Nov 12, 2026

SEC filings12

10-Q · 10-QSEC EDGAR · filed Nov 6, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Nov 5, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Sep 2, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Aug 12, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Jun 22, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 28, 2026 · fetched Nov 12, 2026
10-Q · 10-QSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed May 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 15, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 13, 2026 · fetched Nov 12, 2026
8-K · 8-KSEC EDGAR · filed Apr 13, 2026 · fetched Nov 12, 2026